Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alogliptin Benzoate · 1 trial · 1 indication
Change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was collected at Week 26 relative to Baseline. Mixed model for repeated measures (MMRM) was used for the analysis.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Alogliptin matching-placebo tablets, orally, once daily (QD) for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period. |
| Alogliptin 25 mg | EXPERIMENTAL | Alogliptin 25 mg tablets, orally, QD for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period. |
| Name | Type | Description |
|---|---|---|
| Alogliptin Benzoate | DRUG | Alogliptin benzoate tablets. |
| Placebo | DRUG | Alogliptin placebo-matching tablets. |
Inclusion Criteria: 1. Has a confirmed diagnosis of T2DM using American Diabetes Association (ADA) and World Health Organization (WHO) criteria (laboratory determinations of fasting plasma glucose \[FPG\] greater than or equal to \[\>=\] 126 mg/dL, random glucose \>=200 mg/dL \[\>=11.10 mmol/L\], H...
Alogliptin Benzoate is used for the treatment of Type 2 Diabetes Mellitus. It is a small molecule being developed by Takeda Pharmaceutical Company Limited for this metabolic condition. The drug is currently in Phase 3 clinical development, with one completed trial involving 152 patients.
Alogliptin Benzoate is a small molecule that targets the enzyme dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it helps regulate blood sugar levels in patients with Type 2 Diabetes Mellitus. This mechanism is part of its therapeutic approach for managing the condition.
Alogliptin Benzoate is developed by Takeda Pharmaceutical Company Limited, a company listed on the stock exchange under the ticker symbol TAK. The drug is being investigated for the treatment of Type 2 Diabetes Mellitus and is currently in Phase 3 clinical development.
Alogliptin Benzoate is in Phase 3 clinical development. It is an investigational drug for Type 2 Diabetes Mellitus and has not yet been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug remains under investigation for this indication.
Alogliptin Benzoate has one completed clinical trial, identified as NCT02856113, titled 'Phase 3 Alogliptin Pediatric Study'. This randomized, double-blind, placebo-controlled trial enrolled 152 participants with Type 2 Diabetes Mellitus across multiple countries, including the United States, Brazil, Israel, Italy, Mexico, Poland, and Russia.
Alogliptin Benzoate is a salt form of the drug alogliptin. The benzoate salt is often used in pharmaceutical formulations to improve stability or bioavailability. In clinical trials, the drug is referred to as Alogliptin Benzoate, and it is being studied for the treatment of Type 2 Diabetes Mellitus.